What the placebo arms of the withdrawal trials actually tell us
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
The Ledger in 2024
Page 5 of 11 of this archive, newest first.
Mexico caps dulaglutide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Arab Emirates declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Arab Emirates declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Why a result on one vial says less than the trade needs it to
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The badge economy, and what it is actually certifying
The Journal does not treat a badge as evidence and states so wherever it reports one.
India declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
How a claim degrades between the bench and the listing
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
New Zealand declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Randomised withdrawal is the cleanest design in this field and the least discussed
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Why a result on one vial says less than the trade needs it to
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
The lowest effective dose is a real concept with almost no data behind it
The commonest real-world strategy in this drug class is the least studied one.
Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Randomised withdrawal is the cleanest design in this field and the least discussed
The regain trajectories, arm by arm, with the estimands named.
Spain caps liraglutide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
France declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
The Journal does not treat a badge as evidence and states so wherever it reports one.
From vial to bench: what is recorded and what is assumed
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.